• Sist endret: 21.10.2013
  • Sist revidert: 21.10.2013

Vil du vite mer?

Dette dokumentet er basert på det profesjonelle dokumentet "Hiv-infeksjon og aids" i Norsk Elektronisk Legehåndbok. Referanselisten for dette dokumentet vises nedenfor.

Referanser

  1. Folkehelseinstituttet. HIV-situasjonen i Norge per 31. desember 2012. Smittevernboken 2013.
  2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60. NEJM
  3. Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients with HIV infection. N Engl J Med 2006; 355: 173-81. NEJM
  4. Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005; 353: 1702-10. NEJM
  5. Morris A, Creasman J, Turner J, Luce JM, Wachter RM, Huang L. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166: 262-7. PubMed
  6. Vincent B, Timsit JF, Auburtin M, et al. Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 2004; 30: 859-66. PubMed
  7. Narasimhan M, Posner AJ, DePalo VA, Mayo PH, Rosen MJ. Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. Chest 2004; 125: 1800-4. PubMed
  8. Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004; 18: 1429-33. PubMed
  9. Folkehelseinstituttet. Test og vit. Nov. 2012. http://www.fhi.no/eway/default.aspx?pid=233&t...
  10. Nilsen Ø, Blystad H. Hiv-situasjonen i Norge per 31. desember 2009. MSIS-rapport 17.03.2010.
  11. Aavitsland P, Nilsen Ø. Hivinfeksjon i Norge før 2006. Tidsskr Nor Lægeforen 2006; 126: 3125-30. Tidsskriftet
  12. Bruun JN, Skeie L, Mæland A, Dudman SG, Sannes M, Ormaasen V. Fra dødelig syndrom til kronisk sykdom. Tidsskr Nor Lægeforen 2006; 126: 3121-4. Tidsskriftet
  13. Volmink J. Mother to child transmission of HIV. Clin Evid 2001; 6: 588-95. ClinEvid
  14. The Working Group on MTCT of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results of 13 perinatal studies. J Acquir Immune Defic Syndr 1995; 8: 506-10. PubMed
  15. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282-94. NEJM
  16. Chasela CS, Hudgens MG, Jamieson DJ, et al. Materanl or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362: 2271-81. NEJM
  17. Bakken Kran A-M, Kvale D. Immunpatogenese og terapeutisk immunisering ved hivinfeksjon. Tidsskr Nor Lægeforen 2006; 126: 3112-6. Tidsskriftet
  18. Fisher M, Benn P, Evans B, et al. UK guidelines for the use of post-exposure prophylaxis for hivfollowing sexual exposure. Int J of ST & AIDS 2006; 17: 81-92.
  19. Perinatal HIV Guidelines Working Group Members. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://www.hivatis.org (4.2.2002).
  20. Cooper ER, Charurat M, Mofenson L, Hanson C, Pitt J, Diaz C et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and the prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484 - 94. PubMed
  21. British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIV Medicine 2001; 2: 314 - 34. http://www.bhiva.org.
  22. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621 - 9. NEJM
  23. Nduati R, John G et al. Effect of Breastfeeding and Formula Feeding on Transmission of HIV-1. JAMA 2000; 283:1167-1174. JAMA
  24. Garmark VC, Holmedal SH, Rønsen TK, Bruun JN, Lindemann R, Løkvik BH. HIV-smitte fra mor til barn. Tidsskr Nor Lægeforen 2003; 123: 2029-32. Tidsskriftet
  25. The International Perinatal HIV Group. N Engl J Med 1999; 340: 977-87 NEJM
  26. Ioannidis JPA, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L et al. Pernatal Transmission of Human immunodeficiency Virus Type 1 by Pregnant Women with RNA Loads < 1000 Copies/mL. JID 2001;183:539-45. PubMed
  27. The European Mode of Delivery Collaboration: Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomized clinical trial. Lancet 1999, Mar 27;353:1035-9
  28. Miotti PG, Taha ET, Newton I, et al. HIV transmission through breatfeeding: a study in Malawi. JAMA 1999; 282: 744-9. JAMA
  29. Gerberding JL. Occupational exposure to HIV in health care settings. N Engl J Med 2003; 348: 826-33. NEJM
  30. HIV classification: CDC and WHO staging systems. http://www.aidsetc.org/aidsetc?page=cg-205_hi...
  31. Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis 2004; 38: 1447-53. PubMed
  32. Ormaasen V, Mæland A. Tuberkulose hos HIV-smittede i Norge. Tidsskr Nor Lægeforen 2001; 121: 3425-30. Tidsskriftet
  33. Steinsvoll S, Brokstad Herlofson B. Orale manifestasjoner ved HIV-infeksjon. Tidsskr Nor Lægeforen 2006; 126: 1218-21. Tidsskriftet
  34. Hammer SM, Eron JJ, Reiss P, Schooley RT et al. Antiretroviral Treatment of Adult HIV Infection. 2008. Recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300: 555-70. JAMA
  35. Norsk forening for infeksjonsmedisin. Faglige retningslinjer for oppfølging og behandling av hiv 2013. http://www.oslo-universitetssykehus.no/SiteCo...
  36. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on clinical practices for treatment of HIV infection, mars 2012. http://www.aidsinfo.nih.gov/guidelines/html/1...
  37. European AIDS Clinical Society (EACS). Guidelines version 7.0. October 2013. http://www.eacsociety.org/Portals/0/Guideline...
  38. World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. Nov 30, 2009. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf
  39. Treating HIV-infected people with antoretrovirals protects partners from infection. NIH News, may 2011. http://www.niaid.nih.gov
  40. Ormaasen V. Smittevernveileder. Behandling og foerbygging av tuberkulose hos hivsmittede, okt. 2008.
  41. Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. In: The Cochrane Library, issue 4, 1999. Oxford: Update Software. Cochrane
  42. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomised controlled trials. AIDS 1999; 13: 501-7. PubMed
  43. Trøseid M, Eskesen A, Bruun JN. Immunrekonstitusjonssyndrom ved behandling av hivinfeksjon. Tidsskr Nor Legeforen 2009; 129: 2484-7. Tidsskriftet
  44. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD003510. DOI: 10.1002/14651858.CD003510.pub3. DOI
  45. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software. Cochrane
  46. Goulder PJ, Walker BD. HIV-1 superinfection -- a word of caution. N Engl J Med 2002; 347: 756-8. NEJM
  47. Karim QA, Karim SSA, Frolich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; : DOI:10.1126/science.1193748. DOI
  48. Folkehelseinstituttet. Barnehager og smittevern. Folkehelseinstituttet, januar 2009.
  49. Holm-Hansen C. Vaksiner mot hiv. Tidsskr Nor Lægeforen 2006; 126: 3117-20. Tidsskriftet
  50. Buchbinder S, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-93. PubMed
  51. Bhaskaran K, Mussini C, Antinori A, et al.; CASCADE Collaboration. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63: 213-21. PubMed
  52. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12. PubMed
  53. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 651-81. PubMed
  54. Chu C, Selwyn PA. Complications of HIV infection: a systems-based approach. Am Fam Physician 2011; 83: 395-406. AFP
  55. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-74. PubMed
  56. Bonnet F, Balestre E, Thiébaut R et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine cohort, France. Clin Infect Dis 2006; 42: 411-7. PubMed
  57. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Morb Mortal Weekly Rep 2004; 53(RR-15): 1-112.
  58. Rutherford GW, Lifson AR, Hessol NA et al. Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ 1990; 301: 1183-8. BMJ
  59. Ormaasen V, Sandvik L, Dudman SG et al. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis 2006: akseptert for publisering.
  60. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA 2008; 300: 51-9. JAMA
  61. Bruun JN. Antivirale midler for reduksjon av mor-til-barn-smitte ved HIV-infeksjon. Tidsskr Nor Lægeforen 2003; 123: 2041-2. Tidsskriftet
  62. Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351: 23-32. NEJM
  63. UNAIDS: 2006 report on the global AIDS epidemic. Genève: WHO, 2006. www.unaids.org/en/HIV_data/2006GlobalReport/default.asp
  64. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-9. NEJM
  65. Vu SL, Strat YL, Barin F, et al . Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infectous Diseases 2010; : doi:10.1016/S1473-3099(10)70167-5.
  66. Laine C, Markson LE, McKee LJ, Hauck WW, Fanning TR, Turner BJ. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998; 12: 417-24. PubMed
  67. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection. 2010 recommendations of the International AIDS society-USA panel. JAMA 2010; 304: 321-33. JAMA
  68. Ormaasen V, Bruun JN. Antiviral behandling av kronisk HIV-infeksjon hos voksne. Tidsskr Nor Lægeforen 2001; 121: 3414-20. Tidsskriftet
  69. Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002; 324: 757 - 60. BMJ
  70. Perinatal HIV Guidelines Working Group members. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. www.hivatis.org (4.2.2002).
  71. European Commission. Guidelines for treatment of HIV-positive pregnant women and infants. AIDS 2002; 16 (suppl 2): 1 - 24.
  72. European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035 - 9. PubMed
  73. Castro KG et al.: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Clin Infect Dis 1993; 17: 802-10. PubMed
  74. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200/mm 3
  75. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365: 1031-1038. PubMed
  76. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65. JAMA
  77. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004; 292: 219-23. JAMA
  78. Rutherford GW, Feldman KA, Kennedy GE. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. The Cochrane Library, Issue 2, 2000. Last amendment 22 February, 2000. Cochrane

Debattregler

NHI.no - Norges største helsenettside. Basert på Nordens mest brukte oppslagsverk for leger og helsepersonell (Norsk Elektronisk Legehåndbok).

©2011 Norsk Helseinformatikk AS. Alle rettigheter er reservert. All informasjon på NHI.no er laget for å gi deg generell kunnskap og er ingen erstatning for innhenting av medisinsk råd eller behandling hos helsepersonell. Dersom du er syk eller trenger medisinsk hjelp av andre grunner, bør du oppsøke lege. NHI er uten ansvar for innholdet på eksterne websteder det er lenket til. Vi tillater ikke reklame for behandlere/ behandlingsmetoder i kommentarfeltene. Alle slike innlegg vil bli slettet.